Target-Directed Azide-Alkyne Cycloaddition for Assembling HIV-1 TAR RNA Binding Ligands

Area of Science:

• Biochemistry
• Virology
• Medicinal Chemistry

Background:

• The human immunodeficiency virus type 1 (HIV-1) transactivation response element (TAR) is crucial for viral replication by interacting with the Tat protein.
• Inhibiting Tat-TAR interactions is a key strategy for developing potent HIV-1 antiviral agents.
• HIV-1 TAR RNA serves as a model system for therapeutic intervention.

Purpose of the Study:

• To develop and identify novel ligands that selectively target HIV-1 TAR RNA.
• To investigate the binding sites and specificity of these ligands.
• To assess the potential of these ligands in inhibiting Tat-TAR interactions.

Main Methods:

• Utilized biotin-tagged TAR RNA to synthesize ligands from azide and alkyne building blocks via in situ cycloaddition.
• Employed control templates (TAR DNA and TAR RNA lacking the bulge) to determine ligand selectivity.
• Isolated and identified lead compounds using streptavidin beads.

Main Results:

• Successfully generated triazole-linked thiazole peptidomimetic ligands.
• The primary identified ligand preferentially binds to TAR RNA, specifically in the bulge region.
• Demonstrated specificity for TAR RNA over TAR DNA.
• Confirmed inhibition of Tat-TAR interactions by the lead ligand.

Conclusions:

• Developed a method for assembling TAR RNA-specific ligands.
• Identified a lead compound with potential as an antiviral agent by targeting the Tat-TAR interaction.
• The findings highlight the therapeutic potential of targeting TAR RNA for HIV-1 treatment.